Drug Shortage Report for APO-RIVASTIGMINE

Last updated on 2021-12-03 History
Report ID 141854
Drug Identification Number 02336723
Brand name APO-RIVASTIGMINE
Common or Proper name RIVASTIGMINE
Company Name APOTEX INC
Market Status MARKETED
Active Ingredient(s) RIVASTIGMINE
Strength(s) 3MG
Dosage form(s) CAPSULE
Route of administration ORAL ORAL
Packaging size 100 BTL
ATC code N06DA
ATC description ANTI-DEMENTIA DRUGS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-06-28
Estimated end date 2021-11-30
Actual end date 2021-11-30
Shortage status Resolved
Updated date 2021-12-03
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 150 SIGNET DRIVE
TORONTO, ONTARIO
CANADA M9L 1T9
Company contact information Apotex Customer Service - 1-877-427-6839

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v14 2021-12-03 French Compare
v13 2021-12-03 English Compare
v12 2021-12-01 French Compare
v11 2021-12-01 English Compare
v10 2021-11-19 French Compare
v9 2021-11-19 English Compare
v8 2021-09-15 French Compare
v7 2021-09-15 English Compare
v6 2021-08-06 French Compare
v5 2021-08-06 English Compare
v4 2021-07-29 French Compare
v3 2021-07-29 English Compare
v2 2021-07-05 French Compare
v1 2021-07-05 English Compare

Showing 1 to 14 of 14